Highlights Newsletter 3

This newsletter presents you the following key sessions:

1. PODCAST with prof. Tiziano Barbui about ropeginterferon in patients with polycythemia vera

2. Ibrutinib plus venetoclax confers high rates of undetectable minimal residual disease in the first-line treatment
    of chronic lymphocytic leukaemia

3. Similar safety and efficacy of azacitidine and decitabine in patients with treatment-naïve acute myeloid leukaemia
    who are ineligible for intensive chemotherapy

4. Oral selinexor proves to be safe and effective in patients with primary refractory diffuse large B-cell lymphoma

5. Adding isatuximab to carfilzomib and dexamethasone significantly delays the disease progression of patients
    with relapsed/refractory multiple myeloma